Cantor Fitzgerald Lowers Gilead Sciences (NASDAQ:GILD) Price Target to $115.00

Key Points

• Cantor Fitzgerald cut its price target on Gilead to $115 (from $155) while keeping an "overweight" rating, implying about an 18.6% downside from the recent share price.
• Most analysts remain positive — the consensus rating is a "Moderate Buy" with a consensus target of $156.27 and 24 Buy vs. 4 Hold ratings.
• Gilead posted an earnings and revenue beat for the latest quarter, set FY2026 EPS guidance of $8.45–$8.85, and is accelerating oncology strategy through deals including the planned acquisition of Tubulis for up to $5 billion.

Gilead Sciences (NASDAQ:GILD - Get Free Report) had its target price cut by investment analysts at Cantor Fitzgerald from $155.00 to $115.00 in a report released on Friday,MarketScreener reports. The brokerage currently has an "overweight" rating on the biopharmaceutical company's stock. Cantor Fitzgerald's price objective would indicate a potential downside of 18.62% from the company's current price.

Several other research analysts have also recently weighed in on the stock. Leerink Partners upped their price target on shares of Gilead Sciences from $146.00 to $148.00 and gave the company an "outperform" rating in a report on Wednesday, February 11th. Sanford C. Bernstein reiterated an "outperform" rating and issued a $160.00 price target on shares of Gilead Sciences in a report on Wednesday, February 11th. Wall Street Zen upgraded shares of Gilead Sciences from a "buy" rating to a "strong-buy" rating in a report on Saturday, March 14th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Gilead Sciences from $135.00 to $155.00 and gave the company a "buy" rating in a report on Wednesday, February 11th. Finally, Jefferies Financial Group assumed coverage on shares of Gilead Sciences in a research report on Tuesday, March 10th. They issued a "buy" rating and a $180.00 price objective on the stock. Twenty-four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $156.27.

Gilead Sciences Stock Down 0.5%

Shares of NASDAQ:GILD opened at $141.31 on Friday. Gilead Sciences has a one year low of $93.37 and a one year high of $157.29. The company has a 50 day moving average of $145.19 and a 200-day moving average of $130.18. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. The stock has a market cap of $175.40 billion, a price-to-earnings ratio of 20.88, a P/E/G ratio of 1.88 and a beta of 0.39.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.83 by $0.03. The firm had revenue of $7.93 billion during the quarter, compared to analysts' expectations of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business's revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, sell-side analysts forecast that Gilead Sciences will post 7.95 earnings per share for the current year.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O'day sold 115,640 shares of the company's stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $135.00, for a total value of $15,611,400.00. Following the transaction, the chief executive officer directly owned 566,698 shares in the company, valued at approximately $76,504,230. This represents a 16.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the company's stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total transaction of $617,500.00. Following the completion of the transaction, the director owned 8,920 shares in the company, valued at $1,101,620. This trade represents a 35.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 299,280 shares of company stock valued at $42,820,550 over the last three months. Company insiders own 0.30% of the company's stock.

Institutional Investors Weigh In On Gilead Sciences

Large investors have recently bought and sold shares of the company. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC boosted its stake in shares of Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 85 shares in the last quarter. Corundum Trust Company INC acquired a new stake in shares of Gilead Sciences in the 3rd quarter valued at approximately $26,000. Quattro Advisors LLC acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $26,000. Finally, Wealth Preservation Advisors LLC boosted its stake in shares of Gilead Sciences by 60.0% in the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 81 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Announced acquisition of Tubulis for up to $5 billion to bolster Gilead’s antibody–drug conjugate (ADC) oncology capabilities — strengthens pipeline and R&D capacity. Gilead Sciences (GILD) to Acquire Tubulis for $5B to Strengthen Oncology Pipeline
• Positive Sentiment: Gilead exercised an option to license Kymera’s KT‑200 (oral CDK2 molecular glue degrader), triggering a $45M milestone payment — expands small‑molecule degrader capabilities and pipeline diversity. Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200
• Positive Sentiment: Gilead exercised an option stemming from its Cartography collaboration to license a novel oncology target, further validating external discovery partnerships. Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead’s First Option Target Exercise
• Positive Sentiment: Expanded multi‑year collaboration with Tempus to use real‑world evidence and AI in oncology R&D — supports clinical development and patient selection for Gilead’s cancer programs. Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE
• Positive Sentiment: Truist raised its price target on GILD to $155 (from $152) and reiterated a Buy, citing easing sector headwinds and pickup in deal activity. Gilead price target raised to $155 from $152 at Truist
• Neutral Sentiment: Market commentary notes Gilead’s recent string of buyouts (including Tubulis) signals a strategic shift toward oncology/autoimmune; integration and execution will determine long‑term value. With 3 quick buyouts, Gilead leans into its latest transformation
• Neutral Sentiment: Analyst and media pieces highlight Gilead’s strong earnings‑surprise history and favorable fundamentals, but note the company still must execute on pipeline integration. Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.